Phase 1
Completed N=28
A Drug Drug Interaction (DDI) Study of Selpercatinib (LY3527723) and Rosuvastatin in Healthy Participants
Healthy
Source: ClinicalTrials.gov NCT05906836 ↗
Enrolled (actual)
28
Serious AEs
0.0%
Results posted
Sep 2025
Primary outcomePrimary: Pharmacokinetics (PK): Maximum Concentration (Cmax) of Rosuvastatin — 8.92; 15.2 nanogram per millilitre (ng/mL)
Summary
The main purpose of this study is to determine the effect of selpercatinib on the levels of rosuvastatin in the blood stream in healthy participants. This study also evaluated the safety and tolerability of rosuvastatin when administered in combination with selpercatinib in healthy participants. This study will last up to approximately 26 days excluding screening period.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Pharmacokinetics (PK): Maximum Concentration (Cmax) of Rosuvastatin |
8.92; 15.2 | — |
| PRIMARY PK: Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC[0-∞]) of Rosuvastatin |
81.9; 151 | — |
Eligibility Criteria
Inclusion Criteria
- Participants who are overtly healthy as determined by medical evaluation
- Participant must be Caucasian
- Body mass index (BMI) within the range of 19.0 to 32.0 kilograms per meter squared (kg/m²)
Exclusion Criteria
- Have known allergies to selpercatinib-related compounds or any components of the formulation of selpercatinib, or or rosuvastatin
- • Have a significant previous or current history or presence of cardiovascular, respiratory, renal, gastrointestinal, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; of constituting a risk when taking the investigational product
- Have used or are intending to use over-the-counter or prescription medication, including dietary supplements and herbal medications, within 14 days prior to dosing
Data sourced from ClinicalTrials.gov (NCT05906836). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.